Biotech Volatility and Earnings Pressures Define Mixed Market Session
The equity markets are navigating a complex landscape of 'sell-the-news' reactions and extreme biotech volatility following a series of clinical and financial updates. While Compass Pathways surged on positive trial results, Ocular Therapeutix and Genmab faced significant selling pressure despite reaching key milestones.